The nociceptin/orphanin FQ receptor partial agonist sunobinop promotes non-REM sleep in rodents and patients with insomnia.

Neuroscience Pharmacology Therapeutics

Journal

The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877

Informations de publication

Date de publication:
02 Jan 2024
Historique:
pubmed: 26 10 2023
medline: 26 10 2023
entrez: 26 10 2023
Statut: epublish

Résumé

The potent and partial agonist sunobinop activates the nociceptin/orphanin-FQ peptide receptor and promotes non-REM sleep in rodents and patients with insomnia.

Identifiants

pubmed: 37883189
pii: 171172
doi: 10.1172/JCI171172
doi:
pii:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Garth T Whiteside (GT)

Imbrium Therapeutics, Stamford, Connecticut, USA.

Donald J Kyle (DJ)

Purdue Pharma LP, Stamford, Connecticut, USA.

Ram P Kapil (RP)

Imbrium Therapeutics, Stamford, Connecticut, USA.

Alessandra Cipriano (A)

Imbrium Therapeutics, Stamford, Connecticut, USA.

Ellie He (E)

Imbrium Therapeutics, Stamford, Connecticut, USA.

Mingyan Zhou (M)

Imbrium Therapeutics, Stamford, Connecticut, USA.

Manjunath S Shet (MS)

Imbrium Therapeutics, Stamford, Connecticut, USA.

Michele Hummel (M)

Purdue Pharma LP, Stamford, Connecticut, USA.

Terri Knappenberger (T)

Purdue Pharma LP, Stamford, Connecticut, USA.

Kazuya Fukumura (K)

Shionogi & Co. Ltd., Osaka, Japan.

Yoshiyuki Matsuo (Y)

Shionogi & Co. Ltd., Osaka, Japan.

Masahiro Uehira (M)

Shionogi & Co. Ltd., Osaka, Japan.

Shuichi Hiroyama (S)

Shionogi & Co. Ltd., Osaka, Japan.

Nozomi Takai (N)

Shionogi & Co. Ltd., Osaka, Japan.

Sandra K Willsie (SK)

Pharmaceutical Research Associates, Raleigh, North Carolina, USA.

Stephen C Harris (SC)

Imbrium Therapeutics, Stamford, Connecticut, USA.

Classifications MeSH